Cargando…

Tobramycin administered by the TOBI(®) Podhaler(®) for persons with cystic fibrosis: a review

From its introduction, the antibiotic tobramycin has been an important tool in the management of persons with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa lung infections. Initially an intravenous rescue treatment for pulmonary exacerbations, tobramycin delivered by inhalation has become...

Descripción completa

Detalles Bibliográficos
Autores principales:	VanDevanter, Donald R, Geller, David E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3417888/ https://www.ncbi.nlm.nih.gov/pubmed/22915944 http://dx.doi.org/10.2147/MDER.S16360

Ejemplares similares

Advancing clinical development pathways for new CFTR modulators in cystic fibrosis
por: Mayer-Hamblett, Nicole, et al.
Publicado: (2016)

Population Pharmacokinetics of Inhaled Tobramycin Powder in Cystic Fibrosis Patients
por: Ting, L, et al.
Publicado: (2014)

Edward Tobie, M. D.
Publicado: (1889)

Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations
por: VanDevanter, Donald R, et al.
Publicado: (2010)

Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials
por: VanDevanter, Donald R., et al.
Publicado: (2021)

Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities
por: Nichols, Dave P., et al.
Publicado: (2019)

Long-term safety and efficacy of tobramycin in the management of cystic fibrosis
por: Vázquez-Espinosa, Emma, et al.
Publicado: (2015)

Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis
por: Uttley, Lesley, et al.
Publicado: (2013)

State of progress in treating cystic fibrosis respiratory disease
por: Flume, Patrick A, et al.
Publicado: (2012)

Evidence of Inhaled Tobramycin in Non-Cystic Fibrosis Bronchiectasis
por: Vendrell, Montserrat, et al.
Publicado: (2015)

Azithromycin and Tobramycin Therapy in Cystic Fibrosis Pulmonary Exacerbations: Less Is More?
por: Thornton, Christina, et al.
Publicado: (2021)

Fluctuations in airway bacterial communities associated with clinical states and disease stages in cystic fibrosis
por: Carmody, Lisa A., et al.
Publicado: (2018)

Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin
por: Akkerman-Nijland, Anne M., et al.
Publicado: (2020)

Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder
por: Greenberg, Jonathan, et al.
Publicado: (2016)

Implementation of Model-Based Dose Adjustment of Tobramycin in Adult Patients with Cystic Fibrosis
por: Reverchon, Jérémy, et al.
Publicado: (2022)

Evaluation of the Risk for Acute Kidney Injury in Adult Cystic Fibrosis Patients Receiving Concomitant Vancomycin and Tobramycin
por: Muirhead, Corinne, et al.
Publicado: (2017)

Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence
por: Hamed, Kamal, et al.
Publicado: (2017)

Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis
por: Lam, John, et al.
Publicado: (2013)

Home videos of cystic fibrosis patients using tobramycin inhalation powder: Relation of flow and cough
por: Meerburg, Jennifer J., et al.
Publicado: (2019)

Tobramycin and Amikacin Delay Adhesion and Microcolony Formation in Pseudomonas aeruginosa Cystic Fibrosis Isolates
por: Olivares, Elodie, et al.
Publicado: (2017)

Safety of intravenous tobramycin in combination with a variety of anti-pseudomonal antibiotics in children with cystic fibrosis
por: Deschamp, Ashley R, et al.
Publicado: (2017)

The effect of anthropogenic pressure shown by microbiological and chemical water quality indicators on the main rivers of Podhale, southern Poland
por: Lenart-Boroń, Anna, et al.
Publicado: (2017)

Pharmacokinetics of Tobramycin Administered at the Beginning of Intermittent Hemodialysis Session (ESRD Study)
por: Giroux, Marjolaine, et al.
Publicado: (2021)

Low Molecular Weight Chitosan-Coated PLGA Nanoparticles for Pulmonary Delivery of Tobramycin for Cystic Fibrosis
por: Al-Nemrawi, Nusaiba K., et al.
Publicado: (2018)

Is it Worth Adding Systemic Antibiotics to Inhalational Tobramycin Therapy to Treat Pseudomonas Infections in Cystic Fibrosis?
por: Karki, Kumar, et al.
Publicado: (2021)

Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection
por: Greenwood, James, et al.
Publicado: (2017)

Once daily aerosolised tobramycin in adult patients with cystic fibrosis in the management of Pseudomonas aeruginosa chronic infection
por: Mantero, Marco, et al.
Publicado: (2017)

Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients
por: Stehling, Florian, et al.
Publicado: (2017)

Novel glycopolymer sensitizes Burkholderia cepacia complex isolates from cystic fibrosis patients to tobramycin and meropenem
por: Narayanaswamy, Vidya P., et al.
Publicado: (2017)

Synergistic Activity of Repurposed Peptide Drug Glatiramer Acetate with Tobramycin against Cystic Fibrosis Pseudomonas aeruginosa
por: Murphy, Ronan A., et al.
Publicado: (2022)

Eradication of Burkholderia cepacia complex in cystic fibrosis patients with inhalation of amiloride and tobramycin combined with oral cotrimoxazole
por: Akkerman-Nijland, Anne M., et al.
Publicado: (2023)

Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients
por: Hoppentocht, Marcel, et al.
Publicado: (2016)

The TOBY Study. Whole body hypothermia for the treatment of perinatal asphyxial encephalopathy: A randomised controlled trial
por: Azzopardi, Dennis, et al.
Publicado: (2008)

Mannitol Does Not Enhance Tobramycin Killing of Pseudomonas aeruginosa in a Cystic Fibrosis Model System of Biofilm Formation
por: Price, Katherine E., et al.
Publicado: (2015)

Randomised controlled trial of an iPad based early intervention for autism: TOBY playpad study protocol
por: Granich, Joanna, et al.
Publicado: (2016)

Clinical impact of laboratory error on therapeutic drug monitoring of once-daily tobramycin in cystic fibrosis: Case series
por: Prescott, William A, et al.
Publicado: (2014)

The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: A randomised comparison
por: Prayle, A.P., et al.
Publicado: (2016)

Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis
por: Panguluri, Srilekha, et al.
Publicado: (2017)

Pharmacokinetics and safety of tobramycin nebulization with the I‐neb and PARI‐LC Plus in children with cystic fibrosis: A randomized, crossover study
por: van Velzen, Annelies J., et al.
Publicado: (2019)

Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial
por: Nichols, David P, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_68f90ujove4ojmk3d8d2vpkpm1